MedTrace Logo

Spectrophon LTD Glucometry Monitor Accuracy

NCT03359629 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2019-03-07

Study results available
· View outcomes & findings →

Summary

Diabetes mellitus (or diabetes) is a chronic, metabolic disease characterized by elevated levels of blood glucose. Patients with diabetes need to monitor their blood glucose level several times a day to control their medical state. Modern biosensors have become a promising solution for non-invasive blood glucose measurements. This study aims to validate the efficacy and the accuracy of Glucometry Monitor (NIGM) developed by Spectrophon LTD incorporated in smart watches.

Method Participants will use Spectrophon biosensors to non-invasively estimate the level of glucose in blood. Blood will also be collected and the glucose level will be checked with commercially available blood glucose analyzers . All sets of data will be compared to estimate the accuracy of measurements of Spectrophon NIGM

Conditions

Interventions

DEVICE

Spectrophon Glucometry Monitor

Wearable smartwatch with integrated non-invasive glucose detection system

DEVICE

YSI 2300 Stat Plus

Reference commercial glucometer

Sponsors & Collaborators

  • Ariel University

    collaborator OTHER

  • Tirat Carmel Mental Health Center

    lead OTHER_GOV

Principal Investigators

  • Anatoly Kreinin, MD, PHD · Bruce Rappaport Medical Faculty, Technion, Haifa, Israel

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-27
Primary Completion
2017-10-15
Completion
2017-10-16

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03359629 on ClinicalTrials.gov